Tom Castles

December 18, 2019

Patients with metastatic breast cancer who received an oral version of the chemotherapy drug experienced improved response rates and reductions in peripheral neuropathy compared to those who took the drug intravenously.

December 18, 2019

Patients with early-stage triple-negative breast cancer who did not have circulating tumor DNA in their blood experienced superior outcomes to chemotherapy followed by surgery.

December 16, 2019

Residual cancer burden can help physicians pinpoint accurate long-term predictions about the likelihood that a patient’s breast cancer will return.

December 14, 2019

Women who took estrogen alone as hormone therapy for their menopause experienced decreased rates of breast cancer and death from the disease even after they stopped taking the therapy, when compared to women who took estrogen with progestin.

December 13, 2019

Survival and recurrence rates were similar among patients with breast cancer who either received accelerated partial breast irradiation or whole breast irradiation.

December 13, 2019

Women treated with Arimidex for five years were 50% less likely to have developed breast cancer recurrence compared with women given placebo at nearly 11 years follow-up after stopping treatment.

December 13, 2019

Adding Tecentriq to chemotherapy before surgery did not improve the rate of pathologic complete response in patients with advanced, early-stage triple-negative breast cancer.

December 12, 2019

Nearly 65% of patients whose disease had spread to lymph nodes showed no signs of cancer following a regimen of Keytruda plus chemotherapy compared with those who received chemotherapy alone.

December 12, 2019

Results from a phase 3 trial showed significant increases in five-year invasive disease-free survival estimates among Japanese patients with hormone receptor-positive, HER2-negative breast cancer.

December 12, 2019

Researchers found that the addition of Perjeta to Herceptin plus chemotherapy reduced the relative risk for breast cancer recurrence or death in patients with operable HER2-positive early breast cancer, according to a six-year follow-up.